CAS 739366-20-2
:Anagliptin
Description:
Anagliptin is a pharmaceutical compound classified as a dipeptidyl peptidase-4 (DPP-4) inhibitor, primarily used in the management of type 2 diabetes mellitus. Its mechanism of action involves the inhibition of the DPP-4 enzyme, which leads to increased levels of incretin hormones, thereby enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner. This helps to improve glycemic control. Anagliptin is characterized by its relatively high selectivity for DPP-4, which minimizes potential side effects associated with the inhibition of other enzymes. The compound is typically administered orally and is known for its favorable pharmacokinetic profile, including a moderate half-life that allows for once-daily dosing. Additionally, it has been studied for its potential cardiovascular benefits and effects on weight management. As with other DPP-4 inhibitors, common side effects may include gastrointestinal disturbances and, in rare cases, pancreatitis. Overall, Anagliptin represents a valuable option in the therapeutic arsenal for diabetes management.
Formula:C19H25N7O2
InChI:InChI=1S/C19H25N7O2/c1-13-7-16-21-9-14(11-26(16)24-13)18(28)22-12-19(2,3)23-10-17(27)25-6-4-5-15(25)8-20/h7,9,11,15,23H,4-6,10,12H2,1-3H3,(H,22,28)/t15-/m0/s1
InChI key:InChIKey=LDXYBEHACFJIEL-HNNXBMFYSA-N
SMILES:C(NCC(NCC(=O)N1[C@H](C#N)CCC1)(C)C)(=O)C2=CN3C(N=C2)=CC(C)=N3
Synonyms:- Pyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methyl-
- N-[2-([2-[(2S)-2-Cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
- Suiny
- N-[2-[[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl]amino]-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide
- Anagliptin
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Anagliptin-d6
CAS:Formula:C19H19D6N7O2Color and Shape:White To Off-White SolidMolecular weight:389.49Anagliptin
CAS:<p>Anagliptin (SK-0403) is a potent Inhibitor of DPP-4(IC50 of 3.8 nM), for the treatment of type 2 diabetes mellitus.</p>Formula:C19H25N7O2Purity:97.59% - 99.98%Color and Shape:SolidMolecular weight:383.45Anagliptin
CAS:Controlled Product<p>Applications Anagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction. It also attenuates atherosclerosis in male apolipoprotein E-deficient mice.<br>References Ervinna, N., et al.: Endocrinology, 154, 1260 (2013); Furuta, S., et al.: Eur. J. Drug Metab. Ph., 38, 87 (2013)<br></p>Formula:C19H25N7O2Color and Shape:NeatMolecular weight:383.45(S)-N-(2-((2-(2-CYANOPYRROLIDIN-1-YL)-2-OXOETHYL)AMINO)-2-METHYLPROPYL)-2-METHYLPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBOXAMIDE
CAS:Purity:95.0%Molecular weight:383.45599365234375Anagliptin
CAS:<p>Anagliptin is a dipeptidyl peptidase-4 inhibitor that is used in combination with insulin to treat type 2 diabetes. It has been shown to reduce postprandial blood glucose levels and improve the quality of life for patients with type 2 diabetes. Anagliptin inhibits DPP-IV, which helps regulate blood glucose levels by breaking down proinsulin into insulin. This drug also has anti-inflammatory properties, which may be due to its inhibition of the apoptosis pathway in an injury model system. Anagliptin, when combined with dextran sulfate, can be used as an agent for preventing atherosclerotic lesions in rabbits. The molecular docking analysis revealed that this drug binds to the hydrophobic pocket at the active site of DPP-IV, inhibiting its activity and lowering blood glucose levels.</p>Formula:C19H25N7O2Purity:Min. 96 Area-%Color and Shape:White PowderMolecular weight:383.45 g/mol
![(S)-N-(2-((2-(2-CYANOPYRROLIDIN-1-YL)-2-OXOETHYL)AMINO)-2-METHYLPROPYL)-2-METHYLPYRAZOLO[1,5-A]PYR…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F10%2Fthumb%2FF533681.jpg&w=3840&q=75)
